Pay in 4 interest-free payments of $5.95 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
GLP-1 receptor agonists, like semaglutide and other GLP-1 medications , work through an entirely different mechanism
Those who opt for a Gold Membership get extra perks, like bigger savings, free prescription delivery, and the ability to add family members, friends, and pets to their account
Key Takeaways Gastrointestinal events are the most common adverse effects: Nausea, diarrhea, and vomiting were reported in 4067% of participants at higher doses in published Phase 2 trial data Adverse events are dose-dependent: Higher retatrutide doses consistently produced higher rates of GI events across all published trials Most adverse events were mild to moderate: The Phase 2 trial reported the majority of events as Grade 1-2 in severity Discontinuation rates ranged from 610%: Published data shows dropout rates due to adverse events were comparable to other GLP-1 class compounds Retatrutide is not FDA-approved: All safety data comes from investigational clinical trials it remains a research compound What Clinical Trials Tell Us About Retatrutide Adverse Events Retatrutide (LY3437943) is an investigational triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors simultaneously
Review the medications storage instructions before you go Each version of semaglutide be it Ozempic, Wegovy or Rybelsus should come with a package insert that tells you how to safely store the medication, including the ideal storage temperatures
Actas Dermo-Sifiliogrficas
Ready to feel your best
